Conditions: Postmenopausal Osteoporosis
Keywords: osteoporosis postmenopausal denosumab teriparatide alendronate Forteo® Prolia®
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 27
Healthy volunteers: yes

Brief summary:
The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.

Detailed description:

Arms:
arm 1: Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit. arm 2: Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.

Interventions: intervention 1: Teriparatide 40-mcg subcutaneous injection intervention 2: Denosumab Injection intervention 3: Alendronate Oral Tablet
Intervention descriptions: intervention 1: None intervention 2: One-time Denosumab injection intervention 3: weekly alendronate for 8 weeks

Protocol document: